Results 101 to 110 of about 64,427 (282)

Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? [PDF]

, 2010
Tissue fibrosis causes organ failure and death in patients with systemic sclerosis (SSc), but clearly effective anti-fibrotic therapies are not available.
Beyer, C, Distler, J H W, Distler, O
core   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β

BMC Cancer, 2013
BackgroundMalignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive and associated with poor prognosis. Basic research to develop new treatment regimens is critically needed.MethodsThe effects of imatinib mesylate on MPNSTs were examined in
Jun Ohishi, M. Aoki, K. Nabeshima, J. Suzumiya, T. Takeuchi, A. Ogose, M. Hakozaki, Y. Yamashita, H. Iwasaki   +8 more
semanticscholar   +1 more source

Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia

Haematologica, 2010
As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (
Asim F. Belgaumi, Ali Al-Shehri, Mouhab Ayas, Mohammed Al-Mahr, Amel Al-Seraihy, Ali Al-Ahmari, Hassan El-Solh   +6 more
doaj   +1 more source

BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors [PDF]

, 2019
In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes.
Antolino A., Di Gregorio S., Di Raimondo F., Impera S., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Pennisi M. S., Puma A., Romano C., Siragusa S., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +19 more
core   +1 more source

Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate

PLoS ONE, 2013
Selective inhibition of BCR/ABL expression by RNA interference has been demonstrated as an effective strategy in CML treatment and a reversal to imatinib resistance.
Yajuan Li, Ying Yuan, Kun Tao, Xin Wang, Q. Xiao, Zheng-lan Huang, L. Zhong, Wei-xi Cao, Jian-ping Wen, W. Feng   +9 more
semanticscholar   +1 more source

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)

Acta Medica, 2003
The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj   +1 more source

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

Haematologica, 2008
Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival.
Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Giulia Marzocchi, Simona Bassi, Massimo Breccia, Giuliana Alimena, Ester Pungolino, Giovanna Rege-Cambrin, Riccardo Varaldo, Maurizio Miglino, Giorgina Specchia, Eliana Zuffa, Felicetto Ferrara, Monica Bocchia, Giuseppe Saglio, Fabrizio Pane, Daniele Alberti, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti   +21 more
doaj   +1 more source

Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells But Does Not Affect Tumorigenicity In Vivo [PDF]

, 2004
Platelet-derived growth factor (PDGF) and its cognate receptor are widely expressed on melanomas. Coexpression of the growth factor and receptor suggests their role in autocrine or paracrine growth mechanisms. Imatinib mesylate was previously reported to
Bar-Eli, Menashe, Eton, Omar, Heimberger, Amy, Mcgary, Eric C., Mills, Lisa, Onn, Amir, Shtivelband, Mikhail, Thomas, Gary W.   +7 more
core   +1 more source

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Journal of Clinical Oncology, 2011
PURPOSE Melanomas harbor aberrations in the c-Kit gene. We tested the efficiency of the tyrosine kinase inhibitor imatinib in selected patients with metastatic melanoma harboring c-Kit mutations or amplifications.
Jun Guo, L. Si, Y. Kong, K. Flaherty, Xiaowei Xu, Yanyan Zhu, C. Corless, Li Li, Haifu Li, X. Sheng, C. Cui, Z. Chi, Si-yuan Li, Mei Han, L. Mao, Xuede Lin, N. Du, Xiaoshi Zhang, Junling Li, Baocheng Wang, S. Qin   +20 more
semanticscholar   +1 more source